Table 3:
PCV10 effectiveness against invasive pneumococcal disease outcomes in cases (n=316) and controls (n=1219) in the eff ectiveness analysis
| Exposure* | Contributing strata† | Crude effectiveness (95% CI) | Adjusted effectiveness (95% CI)‡ | |
|---|---|---|---|---|
| Overall | ||||
| Vaccine-type invasive pneumococcal disease§ | Up to date for age for number of PCV10 doses | 61/147 | 86·5% (73·2 to 93·2) | 83·8% (65·9 to 92·3) |
| Vaccine-related invasive pneumococcal disease¶ | Up to date for age for number of PCV10 doses | 21/75 | 83·7% (58·7 to 93·6) | 77·9% (41·0 to 91·7) |
| Non-vaccine-type invasive pneumococcal disease|| | Up to date for age for number of PCV10 doses | 18/94 | 25·4% (−79·2 to 68·9) | 37·5% (−65·4 to 76·4) |
| Children eligible for one catch-up dose at 12–23 months ** | ||||
| Vaccine-type invasive pneumococcal disease | One dose | 29/44 | 70·3% (24·0 to 88·4) | 68·0% (17·6 to 87·6) |
| Vaccine-related invasive pneumococcal disease | One dose | 11/15 | 51·0% (−103·1 to 88·2) | 40·6% (−190·2 to 87·8) |
| Non-vaccine-type invasive pneumococcal disease | One dose | 6/10 | −94·9% (−1047·3 to 66·9) | −72·6% (−972·1 to 72·2) |
| Overall by number of doses†† | ||||
| Vaccine-type invasive pneumococcal disease | At least one dose | 78/147 | 83·7% (70·1 to 91·2) | 81·9% (64·4 to 90·8) |
| Vaccine-type invasive pneumococcal disease | Two doses | 15/124 | 90·5% (72·4 to 96·7) | 89·9% (64·1 to 96·6) |
| Vaccine-type invasive pneumococcal disease | At least two doses | 17/124 | 96·6% (88·6 to 99·0) | 95·9% (84·0 to 98·9) |
| Vaccine-type invasive pneumococcal disease | Three doses | 4/108 | 97·5% (87·2 to 99·5) | 96·4% (80·2 to 99·3) |
| Vaccine-type invasive pneumococcal disease | At least three doses | 5/108 | 96·7% (86·1 to 99·2) | 95·4% (78·1 to 99·0) |
| Vaccine-type invasive pneumococcal disease | Four doses | 1/80 | 73·5% (−20·4 to 94·2) | 67·7% (−58·0 to 93·4) |
| Overall by clinical syndrome | ||||
| Pneumonia or bacteraemia (vaccine-type) | Up to date for age for number of PCV10 doses | 26/75 | 88·2% (67·1 to 95·7) | 81·3% (46·9 to 93·4) |
| Meningitis (vaccine-type) | Up to date for age for number of PCV10 doses | 35/72 | 85·1% (61·6 to 94·2) | 87·7% (61·4 to 96·1) |
| Invasive pneumococcal disease due to individual serotypes | ||||
| 14 | Up to date for age for number of PCV10 doses | 29/72 | 87·2% (61·8 to 95·7) | 87·7% (60·8 to 96·1) |
| 6B | Up to date for age for number of PCV10 doses | 11/32 | 87·5% (47·2 to 97·1) | 82·8% (23·8 to 96·1) |
| 19A | Up to date for age for number of PCV10 doses | 9/26 | 90·2% (56·5 to 97·8) | 82·2% (10·7 to 96·4) |
| 3 | Up to date for age for number of PCV10 doses | 9/28 | 5·5% (−278·4 to 76·4) | 7·8% (−271·9 to 77·1) |
| 6A | Up to date for age for number of PCV10 doses | 6/24 | 36·3% (−184·4 to 85·7) | 14·7% (−311·6 to 82·3) |
| 23F | Up to date for age for number of PCV10 doses | 9/18 | 85·6% (7·7 to 97·7) | 57·8% (−336·7 to 95·9) |
| PCV7 serotypes‡‡ | Up to date for age for number of PCV10 doses | 61/146 | 86·5% (73·2 to 93·2) | 83·2% (64·7 to 92·1) |
PCV10=ten-valent pneumococcal conjugate vaccine. PCV7=seven-valent pneumococcal conjugate vaccine.
Reference used to calculate odds ratio for all exposures was zero doses.
Only strata in which cases and controls had discordant vaccination status contributed to conditional logistic regression models; denominator is the overall number of case-control strata in the subgroup and numerator is the number in the strata with discordance (eg, case vaccinated and at least one control not vaccinated, or case not vaccinated and at least one control vaccinated).
Adjusted for receipt of at least one dose of tetravalent (diphtheria-tetanus-pertussis-Haemophilus influenzae type B) vaccine and any chronic illness.
Includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Includes serotypes not in the vaccine that are of the same serogroup as a vaccine-type.
Includes serotypes that are not vaccine-type or vaccine-related.
Age at least 12 months when PCV10 introduced in the state the child was residing in; eligible for one dose: 69 cases and 261 controls.
The analysis of effectiveness by number of doses does not distinguish between different types of doses (ie, primary, booster or catch-up doses).
PCV7 serotypes include 4, 6B, 9V, 14, 18C, 19F, and 23F.